TY - JOUR T1 - Statistical and agent-based modelling of the transmissibility of different SARS-CoV-2 variants in England and impact of different interventions JF - medRxiv DO - 10.1101/2021.12.30.21267090 SP - 2021.12.30.21267090 AU - J. Panovska-Griffiths AU - B. Swallow AU - R. Hinch AU - J. Cohen AU - K. Rosenfeld AU - R. M. Stuart AU - L. Ferretti AU - F. Di Lauro AU - C. Wymant AU - A. Izzo AU - W. Waites AU - R. Viner AU - C. Bonell AU - The COVID-19 Genomics UK (COG-UK) consortium AU - C. Fraser AU - D. Klein AU - C. C. Kerr Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/03/2021.12.30.21267090.abstract N2 - The English SARS-CoV-2 epidemic has been affected by the emergence of new viral variants such as B.1.177, Alpha and Delta, and changing restrictions. We used statistical models and calibration of an stochastic agent-based model Covasim to estimate B.1.177 to be 20% more transmissible than the wild type, Alpha to be 50-80% more transmissible than B.1.177 and Delta to be 65-90% more transmissible than Alpha. We used these estimates in Covasim (calibrated between September 01, 2020 and June 20, 2021), in June 2021, to explore whether planned relaxation of restrictions should proceed or be delayed. We found that due to the high transmissibility of Delta, resurgence in infections driven by the Delta variant would not be prevented, but would be strongly reduced by delaying the relaxation of restrictions by one month and with continued vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJPG's work was supported by funding from the UK Health Security Agency and the UK Department of Health and Social Care (DHSC). This work was also supported by DHSC funding awarded to CF and Li Ka Shing Foundation grant awarded to CF.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPublicly available data were used in this study and are available upon reasonable request to the authors. https://github.com/Jasminapg/Covid-19-Analysis ER -